1210348-34-7
Ethanediamide impurity A
CAS: 1210348-34-7
Molecular Formula: C16H29N3O7
1210348-34-7 - Names and Identifiers
1210348-34-7 - Physico-chemical Properties
| Molecular Formula | C16H29N3O7 |
| Molar Mass | 375.41736 |
| Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
| Use | Idoseban Intermediate 2 is the starting material and useful component of various drugs. Idoseban Intermediate 2 is an organic synthesis intermediate and a pharmaceutical intermediate. It is mainly used in the laboratory organic synthesis process and the chemical and pharmaceutical research and development process. It can be used as a standard for impurity detection and is mainly suitable for the drug declaration and testing process. |
1210348-34-7 - Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
The primary objective of this study was to compare the safety of four fixed-dose regimens of edoxaban with warfarin in patients with nonvalvular atrial fibrillation (AF). In this 12-week, parallel-group, multi-centre, multinational study, 1,146 patients with AF and risk of stroke were randomised to edoxaban 30 mg qd, 30 mg bid, 60 mg qd, or 60 mg bid or warfarin dose-adjusted to a target international normalised ratio of 2.0–3.0. The study was double-blind to edoxaban dose, but open-label to warfarin. Primary outcomes were occurrence of major and/or clinically relevant non-major bleeding and elevated hepatic enzymes and/or bilirubin. Mean age was 65 ± 8.7 years and 64.4% were warfarin-naïve. Whereas major plus clinically relevant non-major bleeding occurred in 3.2% of patients randomised to warfarin, the incidence of bleeding was significantly higher with the edoxaban 60 mg bid (10.6%; p=0.002) and 30 mg bid regimens (7.8%; p=0.029), but not with the edoxaban 60 mg qd (3.8%) or 30 mg qd regimens (3.0%). For the same total daily dose of 60 mg, both bleeding frequency and trough edoxaban concentrations were higher in the 30-mg bid group than in the 60-mg qd group. There were no significant differences in hepatic enzyme elevations or bilirubin values among the groups. The safety profiles of edoxaban 30 and 60 mg qd in patients with AF were similar to warfarin. In contrast, the edoxaban bid regimens were associated with more bleeding than warfarin. These results suggest that in this three-month study, edoxaban 30 or 60 mg qd are safe and well-tolerated.
Last Update：2024-01-02 23:10:35
1210348-34-7 - Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
Edoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The objectives of the present analyses were to characterise edoxaban population pharmacokinetics (PPK) and identify potential intrinsic and extrinsic factors affecting variability in edoxaban exposure, determine if there are relationships between edoxaban pharmacokinetics or biomarkers and the risk of bleeding in patients with NVAF using an exposure-response model, and to use the PPK and exposure-response model to support dose selection for a phase III trial of edoxaban in patients with NVAF. PPK analysis of data from 1,281 edoxaban-dosed subjects with intrinsic factors such as renal impairment or NVAF and extrinsic factors such as concomitant medications revealed significant effects of renal impairment and concomitant strong P-glycoprotein (P-gp) inhibitors on the pharmacokinetics of edoxaban. Exposure-response analysis found that in patients with NVAF, the incidence of bleeding events increased significantly with increasing edoxaban exposure, with steady-state minimum concentration (Cmin,ss) showing the strongest association. Clinical trial simulations of bleeding incidence were used to select 30 mg and 60 mg once-daily edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-gp inhibitors as the treatment regimens in the ENGAGE AF-TIMI 48 (NCT00781391) trial.
The results of this study were previously presented at the 2009 International Society on Thrombosis and Haemostasis, July 2009, Boston, Massachusetts, USA.
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: Edoxaban Impurity 29 Visit Supplier Webpage Request for quotationCAS: 1210348-34-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: tert-Butyl[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate Visit Supplier Webpage Request for quotation
CAS: 1210348-34-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1210348-34-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate Request for quotation
CAS: 1210348-34-7
Tel: 021-60290089
Email: dshs21@eagle-pharm.com
Mobile: 18701839918
QQ: 2965663228
Send QQ message
CAS: 1210348-34-7
Tel: 021-60290089
Email: dshs21@eagle-pharm.com
Mobile: 18701839918
QQ: 2965663228
Spot supply
Product Name: Edoxaban Impurity 29 Visit Supplier Webpage Request for quotationCAS: 1210348-34-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: tert-Butyl[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate Visit Supplier Webpage Request for quotation
CAS: 1210348-34-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1210348-34-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate Request for quotation
CAS: 1210348-34-7
Tel: 021-60290089
Email: dshs21@eagle-pharm.com
Mobile: 18701839918
QQ: 2965663228Send QQ message
CAS: 1210348-34-7
Tel: 021-60290089
Email: dshs21@eagle-pharm.com
Mobile: 18701839918
QQ: 2965663228
View History